JP6836700B2 - 敗血症患者血中エンドトキシン測定のための試料調整方法 - Google Patents
敗血症患者血中エンドトキシン測定のための試料調整方法 Download PDFInfo
- Publication number
- JP6836700B2 JP6836700B2 JP2017137221A JP2017137221A JP6836700B2 JP 6836700 B2 JP6836700 B2 JP 6836700B2 JP 2017137221 A JP2017137221 A JP 2017137221A JP 2017137221 A JP2017137221 A JP 2017137221A JP 6836700 B2 JP6836700 B2 JP 6836700B2
- Authority
- JP
- Japan
- Prior art keywords
- blood
- endotoxin
- plasma
- dextran
- sample
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000002158 endotoxin Substances 0.000 title claims description 97
- 239000008280 blood Substances 0.000 title claims description 59
- 210000004369 blood Anatomy 0.000 title claims description 58
- 238000005259 measurement Methods 0.000 title claims description 25
- 238000005464 sample preparation method Methods 0.000 title description 3
- 238000000034 method Methods 0.000 claims description 66
- 210000000265 leukocyte Anatomy 0.000 claims description 44
- 229920002307 Dextran Polymers 0.000 claims description 39
- 210000003743 erythrocyte Anatomy 0.000 claims description 12
- 239000003153 chemical reaction reagent Substances 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 239000006228 supernatant Substances 0.000 claims description 3
- 238000004220 aggregation Methods 0.000 claims 1
- 230000002776 aggregation Effects 0.000 claims 1
- 238000011534 incubation Methods 0.000 claims 1
- 241000239218 Limulus Species 0.000 description 22
- 238000012360 testing method Methods 0.000 description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 238000010438 heat treatment Methods 0.000 description 10
- 206010040047 Sepsis Diseases 0.000 description 9
- 238000001816 cooling Methods 0.000 description 9
- 241001529572 Chaceon affinis Species 0.000 description 8
- 229920001612 Hydroxyethyl starch Polymers 0.000 description 7
- 210000000601 blood cell Anatomy 0.000 description 7
- 238000010790 dilution Methods 0.000 description 7
- 239000012895 dilution Substances 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 229940050526 hydroxyethylstarch Drugs 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 6
- 238000001879 gelation Methods 0.000 description 6
- 230000035931 haemagglutination Effects 0.000 description 6
- 238000000691 measurement method Methods 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 210000000170 cell membrane Anatomy 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- 230000037361 pathway Effects 0.000 description 5
- FYGDTMLNYKFZSV-WFYNLLPOSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,3s,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-WFYNLLPOSA-N 0.000 description 4
- 229920002498 Beta-glucan Polymers 0.000 description 4
- 239000000701 coagulant Substances 0.000 description 4
- 230000000415 inactivating effect Effects 0.000 description 4
- 230000002452 interceptive effect Effects 0.000 description 4
- 229920006008 lipopolysaccharide Polymers 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 3
- 206010040070 Septic Shock Diseases 0.000 description 3
- 108010000499 Thromboplastin Proteins 0.000 description 3
- 102000002262 Thromboplastin Human genes 0.000 description 3
- 229920004890 Triton X-100 Polymers 0.000 description 3
- 239000013504 Triton X-100 Substances 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000007865 diluting Methods 0.000 description 3
- 238000005534 hematocrit Methods 0.000 description 3
- 230000002779 inactivation Effects 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 230000036303 septic shock Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108090000056 Complement factor B Proteins 0.000 description 2
- 102000003712 Complement factor B Human genes 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 101710154606 Hemagglutinin Proteins 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 102000052508 Lipopolysaccharide-binding protein Human genes 0.000 description 2
- 108010053632 Lipopolysaccharide-binding protein Proteins 0.000 description 2
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 2
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 2
- 101710176177 Protein A56 Proteins 0.000 description 2
- 102000002689 Toll-like receptor Human genes 0.000 description 2
- 108020000411 Toll-like receptor Proteins 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 201000005008 bacterial sepsis Diseases 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000015271 coagulation Effects 0.000 description 2
- 238000005345 coagulation Methods 0.000 description 2
- 108010045487 coagulogen Proteins 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 231100000284 endotoxic Toxicity 0.000 description 2
- 230000002346 endotoxic effect Effects 0.000 description 2
- 108010072542 endotoxin binding proteins Proteins 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 239000000185 hemagglutinin Substances 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 230000010355 oscillation Effects 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 238000010257 thawing Methods 0.000 description 2
- 102100039140 Acyloxyacyl hydrolase Human genes 0.000 description 1
- 102000004411 Antithrombin III Human genes 0.000 description 1
- 108090000935 Antithrombin III Proteins 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 241000239216 Carcinoscorpius Species 0.000 description 1
- 102100038608 Cathelicidin antimicrobial peptide Human genes 0.000 description 1
- 101710140438 Cathelicidin antimicrobial peptide Proteins 0.000 description 1
- 108010074860 Factor Xa Proteins 0.000 description 1
- 101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 description 1
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 1
- 102100025390 Integrin beta-2 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 1
- 208000034486 Multi-organ failure Diseases 0.000 description 1
- 208000010718 Multiple Organ Failure Diseases 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 101710160107 Outer membrane protein A Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000239222 Tachypleus Species 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 108010008855 acyloxyacyl hydrolase Proteins 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000004523 agglutinating effect Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 102000003801 alpha-2-Antiplasmin Human genes 0.000 description 1
- 108090000183 alpha-2-Antiplasmin Proteins 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229960005348 antithrombin iii Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000000149 argon plasma sintering Methods 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- POIUWJQBRNEFGX-XAMSXPGMSA-N cathelicidin Chemical compound C([C@@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(C)C)C1=CC=CC=C1 POIUWJQBRNEFGX-XAMSXPGMSA-N 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 230000001112 coagulating effect Effects 0.000 description 1
- LOHQECMUTAPWAC-UHFFFAOYSA-N coagulin Natural products C1C(C)=C(CO)C(=O)OC1C1(C)C(C2(C)CCC3C4(C(=O)CC=CC4=CCC43)C)(O)CCC24O1 LOHQECMUTAPWAC-UHFFFAOYSA-N 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000020176 deacylation Effects 0.000 description 1
- 238000005947 deacylation reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 208000027096 gram-negative bacterial infections Diseases 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 102000014452 scavenger receptors Human genes 0.000 description 1
- 108010078070 scavenger receptors Proteins 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000002344 surface layer Substances 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Images
Landscapes
- Investigating Or Analysing Biological Materials (AREA)
Description
Claims (6)
- 採取した血液を直ちに37℃に保温し、予め血液を保温する温度と同じ温度に保温した血 液と等張の溶液に溶解したデキストラン溶液を加えて37℃で静置して得た多白血球血漿を試料とすることを特徴とする血液エンドトキシン測定用試料の作成法。
- 血液と等張の溶液に溶解したデキストラン溶液と血液の混合物を静置する時間が赤血球が沈降して上澄みの多白血球血漿が分離される時間である請求項1に記載の血液エンドトキシン測定用試料の作成法。
- 試料がヒト又は動物の血液である、請求項1または2に記載のエンドトキシン測定用試料の作成法。
- 赤血球凝集能を有し、血液と等張の溶液に溶解した請求項1から3までに記載の血液エンドトキシン測定用試料作成法に用いる37℃に保温されたデキストラン溶液からなる試薬。
- 血液と等張の溶液に溶解したデキストラン溶液の濃度(W/V%)が0.1から6%である請求項4に記載の血液エンドトキシン測定用試料作成に用いる試薬。
- 血液と等張の溶液に溶解したデキストラン溶液はエンドトキシンフリーである請求項4ま たは5に記載の血液エンドトキシン測定用試料作成に用いる試薬。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2017137221A JP6836700B2 (ja) | 2017-07-13 | 2017-07-13 | 敗血症患者血中エンドトキシン測定のための試料調整方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2017137221A JP6836700B2 (ja) | 2017-07-13 | 2017-07-13 | 敗血症患者血中エンドトキシン測定のための試料調整方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2019020196A JP2019020196A (ja) | 2019-02-07 |
JP6836700B2 true JP6836700B2 (ja) | 2021-03-03 |
Family
ID=65355479
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017137221A Active JP6836700B2 (ja) | 2017-07-13 | 2017-07-13 | 敗血症患者血中エンドトキシン測定のための試料調整方法 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP6836700B2 (ja) |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2461969A1 (de) * | 1974-12-31 | 1976-07-08 | Behringwerke Ag | Stabiles blutplasma, verfahren zu dessen herstellung und seine verwendung als vergleichsplasma bei gerinnungs- untersuchungen |
US5397479A (en) * | 1993-04-26 | 1995-03-14 | International Remote Imaging Systems, Inc. | Composition and method for enrichment of white blood cells from whole human blood |
US6159683A (en) * | 1997-12-16 | 2000-12-12 | Spectral Diagnostics, Inc. | Method of determining stage of sepsis |
JP4761448B2 (ja) * | 2005-09-16 | 2011-08-31 | 独立行政法人科学技術振興機構 | 血液エンドトキシン測定方法 |
JP2007315780A (ja) * | 2006-05-23 | 2007-12-06 | Sekisui Chem Co Ltd | 細胞機能測定方法 |
JP2013124905A (ja) * | 2011-12-14 | 2013-06-24 | Katsuya Inada | 血液エンドトキシン測定用試料作成方法 |
-
2017
- 2017-07-13 JP JP2017137221A patent/JP6836700B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
JP2019020196A (ja) | 2019-02-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4761448B2 (ja) | 血液エンドトキシン測定方法 | |
US9389222B2 (en) | Urinary biomarkers for predicting long-term dialysis | |
JP6018923B2 (ja) | 敗血症の予後の予測方法 | |
CN102421799B (zh) | 用于高分子脂联素分析的新型单克隆抗体及其应用 | |
JPS60502167A (ja) | 軟骨に生じる変化の測定法 | |
CN104459105B (zh) | 一种检测lp的胶乳增强免疫比浊试剂盒及其制备方法 | |
CN104407157B (zh) | 一种离子稳定剂和悬浮稳定剂配合使用的检测瘦素的胶乳增强免疫比浊试剂盒 | |
CN107255711B (zh) | 骨桥蛋白用于制备或筛选慢加急性肝衰竭诊断试剂的用途 | |
CN106556703A (zh) | 一种慢性肾脏病标志物suPAR检测试剂盒和制备方法 | |
Shaw et al. | Use of serum hyaluronic acid as a biomarker of endothelial glycocalyx degradation in dogs with septic peritonitis | |
JP2013124905A (ja) | 血液エンドトキシン測定用試料作成方法 | |
JP6836700B2 (ja) | 敗血症患者血中エンドトキシン測定のための試料調整方法 | |
CN106170698A (zh) | β‑葡聚糖测定方法 | |
CN109001453B (zh) | 一种基于胶乳免疫比浊法检测人体液样本中溶菌酶含量的试剂盒 | |
Baghezza et al. | Pathological study and detection of Bovine parainfluenza 3 virus in pneumonic sheep lungs using direct immunofluorescence antibody technique | |
Brunner et al. | Analysis of the classical, alternative, and mannose binding lectin pathway of the complement system in the pathogenesis of oligoarticular juvenile idiopathic arthritis | |
Sonderegger et al. | Association of markers of endothelial activation and dysfunction with occurrence and outcome of pulmonary hemorrhage in dogs with leptospirosis | |
JP5016676B2 (ja) | 免疫系の活性化または細胞死の程度の検出のための方法 | |
CN106093373A (zh) | 一种测定透明质酸的试剂盒 | |
Aşık et al. | An evaluation of platelet parameters and neutrophil/lymphocyte ratios in children with acute rheumatic fever | |
Mubaraki et al. | Biochemical and hematological markers as brucellosis indicators in the najran region of Saudi Arabia | |
RU2704121C1 (ru) | Скрининг-тест для определения функциональной активности классического пути системы комплемента | |
WO2009111485A2 (en) | Infection mediated foam dissolution rate measurement | |
Ismail et al. | Acute phase response and some hematobiochemical alterations in some selected canine disease. | |
Palmiere et al. | Postmortem serum protein growth arrest-specific 6 levels in sepsis-related deaths |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190919 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20200710 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200804 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200929 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200929 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20201222 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210108 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6836700 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |